STANDARD OF CARE TEMOZOLOMIDE CHEMOTHERAPY ± TUMOR TREATING FIELDS (TTFIELDS) IN NEWLY DIAGNOSED GLIOBLASTOMA. FINAL RESULTS OF THE PHASE III EF-14 CLINICAL TRIAL

被引：0

作者：

Stupp, R. ^{[1
,2
]}

Ram, Z. ^{[3
]}

机构：

[1] Univ Zurich, Zurich, Switzerland

[2] EF 14 Investigators, Zurich, Switzerland

[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

来源：

NEURO-ONCOLOGY | 2017年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OS07.9

引用

页码：15 / 15

页数：1

共 50 条

[31] Phase III trial of tumor-treating fields (TTFields) together with temozolomide compared with temozolomide (TMZ) alone in patients with newly diagnosed glioblastoma multiforme (NCT00916409).
Kesari, Santosh
Taillibert, Sophie
Kanner, Andrew
Weinberg, Uri
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[32] TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) IN THE EF-14 PHASE 3 CLINICAL STUDY - A SAFETY ANALYSIS
Kinzel, Adrian
Lavy-Shahaf, Gitit
Kirson, Eilon
NEURO-ONCOLOGY, 2018, 20 : 23 - 23
[33] TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) IN THE EF-14 PHASE 3 CLINICAL STUDY - A SAFETY ANALYSIS
Kinzel, A.
Lavy-Shahaf, G.
Kirson, E.
NEURO-ONCOLOGY, 2018, 20 : 244 - 244
[34] EFFICACY OF TTFIELDS IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) - SUB-GROUP ANALYSIS OF THE EF-14 TRIAL
Ram, Zvi
Kim, Chae-Yong
Zhu, Jay-Jiguang
NEURO-ONCOLOGY, 2020, 22 : 58 - 58
[35] Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy/temozolomide in newly diagnosed glioblastoma
Shi, Wenyin
Roberge, David
Kleinberg, Lawrence
Jeyapalan, Suriya A.
Goldlust, Samuel Aaron
Nagpal, Seema
Lustgarten, Leonardo
Combs, Stephanie E.
Nishikawa, Ryo
Reardon, David A.
Grossman, Rachel
Glas, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients
Mehta, M.
Wen, P.
Nishikawa, R.
Reardon, D.
Peters, K.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 111 : 60 - 65
[37] INCREASED COMPLIANCE WITH TUMOR TREATING FIELDS IS PROGNOSTIC FOR IMPROVED SURVIVAL IN THE TREATMENT OF GLIOBLASTOMA: A SUBGROUP ANALYSIS OF THE EF-14 PHASE III TRIAL
Ram, Z.
NEURO-ONCOLOGY, 2018, 20 : 235 - 236
[38] Final results of a randomized phase III trial of nimotuzumab for the treatment of newly diagnosed glioblastoma in addition to standard radiation and chemotherapy with temozolomide versus standard radiation and temoziolamide
Westphal, Manfred
Bach, Ferdinand
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[39] Safety analysis of Tumor Treating Tields (TTFields) combined with lomustine in the EF-14 phase 3 trial
Kinzel, A.
Lavy-Shahaf, G.
Kirson, E. D.
STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S111 - S111
[40] Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma-First report of the full dataset of the EF14 randomized phase III trial
Stupp, Roger
Taillibert, Sophie
Kanner, Andrew
Kesari, Santosh
Toms, Steven A.
Barnett, Gene H.
Fink, Karen L.
Silvani, Antonio
Lieberman, Frank S.
Zhu, Jay-Jiguang
Taylor, Lynne Patricia
Honnorat, Jerome
Hottinger, Andreas
Chen, Thomas
Tran, David Dinh
Kim, Chae-yong
Hirte, Hal W.
Hegi, Monika E.
Palti, Yoram
Ram, Zvi
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →